The lower doses are associated with lower risk of adverse effects with almost unaffected benefits in terms of improving hyperglycemia and insulin sensitivity, and lowering cancer risk in both direct and indirect mechanisms [95,96,97]. The gene discussed is INS; the disease is cancer.